InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
0.00%
)
US TECH 100
16,995.60
(
0.80%
)
Dow Jones
37,903.29
(
0.00%
)
Brent Oil
83.59
(
0.05%
)
Bitcoin
58,768.34
(
0.91%
)
Post# of 251673
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

xavierprivas

Send PM Follow Ignore
Followers 6
Posts 160
Boards Moderated 0
Alias Born 09/14/2009

xavierprivas

Re: iwfal post# 251420

Sunday, 04/07/2024 11:54:23 AM

Sunday, April 07, 2024 11:54:23 AM

Post# of 251673
If you look at slide 12 then OCUL Paxtrava has no endothelial cell loss
https://investors.ocutx.com/static-files/7d4551c6-1158-4a4b-a13a-2198a210de00

vs Durysta
https://pubmed.ncbi.nlm.nih.gov/34586961/

OTOH Paxtrava has more adverse events in slide 13
PS I have OCUL shares so the above analysis can be biased, not a promotion of OCUL
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up